ArticlePloS one2013
Latent microsporidiosis caused by Encephalitozoon cuniculi in immunocompetent hosts: a murine model demonstrating the ineffectiveness of the immune system and treatment with albendazole.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 69 citations in OpenAlex.
- Interstitial pneumonia via the oropharyngeal route of infection with Encephalitozoon cuniculi.PLoS neglected tropical diseases · 2025Article
- Encephalitozoon cuniculi Microsporidia in Cerebrospinal Fluid from Immunocompetent Patients, Czech Republic.Emerging infectious diseases · 2024Article
- Microsporidia (Encephalitozoon cuniculi) in Patients with Degenerative Hip and Knee Disease, Czech Republic.Emerging infectious diseases · 2024Article
- Molecular Prevalence of Microsporidia Infection in Patients with Lung Cancer.The American journal of tropical medicine and hygiene · 2023Article
- A multidisciplinary review about Encephalitozoon cuniculi in a One Health perspective.Parasitology research · 2022Review
- Comparison of the Concentration ofJournal of inflammation research · 2022Article
- Chronic Infections in Mammals Due to Microsporidia.Experientia supplementum (2012) · 2022Article
- Immune Response to Microsporidia.Experientia supplementum (2012) · 2022Article
- Sparse Evidence forPathogens (Basel, Switzerland) · 2021Article
- Intestinal Microsporidia Infection in Leukemic Children: Microscopic and Molecular Detection.Acta parasitologica · 2021Article
- Characterization of a Murine Model forMicroorganisms · 2020Article
- Encephalitozoon cuniculi Genotype III Evinces a Resistance to Albendazole Treatment in both Immunodeficient and Immunocompetent Mice.Antimicrobial agents and chemotherapy · 2020Article
- Innate and Adaptive Immune Responses Against Microsporidia Infection in Mammals.Frontiers in microbiology · 2020Review
- Article
- IL-21 Is Important for Induction of KLRG1+ Effector CD8 T Cells during Acute Intracellular Infection.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Prevention and treatment ofIranian journal of veterinary research · 2016Article
- Microsporidiosis in Vertebrate Companion Exotic Animals.Journal of fungi (Basel, Switzerland) · 2015Review
- Interleukin-12-producing CD103+ CD11b- CD8+ dendritic cells are responsible for eliciting gut intraepithelial lymphocyte response against Encephalitozoon cuniculi.Infection and immunity · 2015Article
- Microsporidia-host interactions.Current opinion in microbiology · 2015Review
- Encephalitozoonosis in 2 South American Fur Seal (Arctocephalus australis) Pups.Veterinary pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicrosporidia are obligate intracellular parasites causing severe infections with lethal outcome in immunocompromised hosts. However, these pathogens are more frequently reported as latent infections in immunocompetent individuals and raises questions about the potential risk of reactivation following induced immunosuppression.
aimsTo evaluate the possibility latent microsporidiosis, efficacy or albendazole, and reactivation, the authors monitored the course of E. cuniculi infection in immunocompetent BALB/c mice and immunodeficient SCID mice using molecular methods.
methodsMice were per orally infected with 10(7) spores of E. cuniculi. Selected groups were treated with albendazole, re-infected or chemically immunosuppressed by dexamethasone. The presence of microsporidia in the host's organs and feces were determined using PCR methods. Changes in numbers of lymphocytes in blood and in spleen after induction of immunosuppression were confirmed using flow cytometry analysis.
resultsWhereas E. cuniculi caused lethal microsporidiosis in SCID mice, the infection in BABL/c mice remained asymptomatic despite parasite dissemination into many organs during the acute infection phase. Albendazole treatment led to microsporidia elimination from organs in BALB/c mice. In SCID mice, however, only a temporary reduction in number of affected organs was observed and infection re-established post-treatment. Dexamethasone treatment resulted in a chronic microsporidia infection disseminating into most organs in BALB/c mice. Although the presence of E. cuniculi in organs of albendazole- treated mice was undetectable by PCR, it was striking that infection was reactivated by immunosuppression treatment.
conclusionOur results demonstrated that microsporidia can successfully survive in organs of immunocompetent hosts and are able to reactivate from undetectable levels and spread within these hosts after induction of immunosuppression. These findings stress the danger of latent microsporidiosis as a life-threatening risk factor especially for individuals undergoing chemotherapy and in transplant recipients of organs originating from infected donors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.